Report: The bitterest pill - Decision making for high cost drugs

December 20, 1997 by Accounts Commission

Patient access to high cost drugs varies from health board to health board because of differences in their drug prescribing policies. The Commission is calling for a Scotland-wide policy group to evaluate high cost, low volume drugs and make recommendations to health boards about their clinical and cost-effectiveness. Such an approach would bring the NHS in Scotland a step closer to ensuring equal access to these drugs based on need.

Main report - PDF 137Kb Share this LinkedIn 0